| Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More | Frank Vinluan | 12/13/19 | National |
| Neuroscience Is Taking the Spotlight at Xconomy’s Bay Area Xchange | Frank Vinluan | 11/11/19 | San Francisco |
| Eying “Extra” DNA As Cancer Driver, Boundless Bio Debuts With $46M | Sarah de Crescenzo | 09/19/19 | San Diego |
| Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds | Frank Vinluan | 09/06/19 | Boston |
| Synthorx Gets $131M in Upsized IPO for Synthetic Biology Drugs | Sarah de Crescenzo | 12/07/18 | San Diego |
| BlackThorn Emerges With $40M, New Weapons Against Neuro Disorders | Ben Fidler | 10/20/16 | San Francisco |
| Third Rock, SR One Put $52M Into Decibel to Battle Hearing Loss | Ben Fidler | 10/15/15 | Boston |
| La Jolla Immunology Institute Agrees to Formal Ties with UCSD | Bruce V. Bigelow | 07/29/15 | San Diego |
| Now Playing: California’s $1 Billion Stem-Cell Renovation Show | Alex Lash | 02/03/15 | National |
| From Yeast, Yumanity Looks to Give Rise to Critical Neuro Drugs | Ben Fidler | 01/26/15 | Boston |
| West Coast Biotech Roundup: Gilead/AbbVie, Juno, Auspex, Bina & More | Alex Lash | 12/23/14 | San Francisco |
| West Coast Biotech Roundup: Ebola, Mapp, Tekmira, ViaCyte & More | Alex Lash | 08/21/14 | San Diego |
| West Coast Biotech Roundup: IPOs, Gilead, Sofinnova, & Denouements | Bruce V. Bigelow | 07/25/14 | San Diego |
| West Coast Biotech Roundup: Scripps, Trounson, Versant, Gilead, & More | Alex Lash | 07/10/14 | San Francisco |
| Langer, Led Zeppelin, and Hookups: Three Days Behind the BIO Scenes | Alex Lash | 06/27/14 | San Diego |
| West Coast Biotech Roundup: Alder IPO, Exelixis, Corcept, and More | Bruce V. Bigelow | 05/09/14 | San Diego |
| San Diego’s Synthorx Adds To Genetic Alphabet, Aims for Bio-Products | Bruce V. Bigelow | 05/07/14 | San Diego |
| Scripps Unveils New Drug Development Arm, Signs J&J as First Partner | Bernadette Tansey | 04/15/14 | San Francisco |
| Fate Therapeutics Joins Biotech IPO Conga Line, Reaching for $69M | Luke Timmerman | 08/14/13 | San Diego |
| San Diego Life Sciences Roundup: Regulus, Ocera, Lithera, and More | Bruce V. Bigelow | 07/18/13 | San Diego |
| MD Revolution Offers Blueprint for “Health Management” Practice | Bruce V. Bigelow | 06/26/13 | National |
| San Diego Life Sciences Roundup: Receptos, Arena, NuVasive, & More | Bruce V. Bigelow | 05/09/13 | San Diego |
| Live! Anderson & Ferrara Headline Rock Stars of Innovation Summit | Bruce V. Bigelow | 03/26/13 | San Diego |
| San Diego’s Biotech Leaders of Tomorrow: ‘We Are the Wildcatters’ | Bruce V. Bigelow | 02/27/13 | San Diego |
| In VC ‘Hat Trick’ for San Diego’s Avalon, RQx Inks Genentech Deal | Bruce V. Bigelow | 02/12/13 | San Diego |
| The Fiscal Cliff Is Forcing a Biomedical Day of Reckoning | Luke Timmerman | 12/31/12 | National |
| San Diego Life Sciences Roundup: Acadia, RQx, and Venture Funding | Bruce V. Bigelow | 11/30/12 | San Diego |
| Stanford’s Mike Snyder is Showing the Way With Personalized Medicine | Luke Timmerman | 11/19/12 | National |
| San Diego Life Sciences Roundup: Shire, Thesan, ViaCyte, and More | Bruce V. Bigelow | 11/02/12 | San Diego |
| Domain-Backed Adynxx Enters the Wide Open World of Pain Drug R&D | Luke Timmerman | 08/07/12 | San Francisco |
